Forget NuScale: This Nuclear Energy Stock Is the Smarter Bet Right Now

NuScale has fallen back to about $10 per share from its October 2025 peak of $53.43 after canceling its Idaho project, delaying Romanian commercial deployments from 2030 to 2033, and losing its key RoPower-related revenue stream. Analysts expect 2026 revenue to decline 21% to $25 million and net loss to reach $181 million, leaving the company valued at roughly 169x sales. The article favors BWX Technologies, citing its $7.3 billion backlog, 50% year-over-year increase, and expected 2025-2028 revenue and EPS CAGRs of 12% and 16%, respectively.

Analysis

The actionable distinction is not simply profitable incumbent versus pre-revenue developer: BWXT monetizes nuclear demand through constrained manufacturing capacity, qualified labor, and regulated-material handling, where customer qualification cycles make substitution difficult. That should allow backlog conversion to support pricing and margin resilience even if commercial SMR projects slip; defense and naval programs also make its earnings duration less correlated with power-market economics. The acquisition integration is the nearer-term swing factor: successful cross-selling and procurement savings could support upside to consensus over the next 12-24 months, while a weak integration would expose that the current valuation already discounts a clean execution path.

SMR is effectively valued as a long-duration option on project financing, customer contracting, fuel availability, and regulatory schedules rather than near-term revenue. The loss of engineering revenue raises the probability of incremental capital needs before an operating asset validates unit economics; dilution risk matters more than a conventional sales multiple for the next 6-18 months. This also weakens the read-through to the broader nuclear theme: reactor developers may remain funding-constrained even as suppliers such as BWXT, Cameco (CCJ), Centrus (LEU), and Curtiss-Wright (CW) benefit from government-supported fuel-cycle and nuclear-defense spending.

Consensus may be too quick to treat BWXT as a pure safe haven. Its premium multiple leaves limited tolerance for Navy procurement timing, fixed-price execution, or acquisition-related margin drag, and commercial-nuclear enthusiasm has already pulled forward part of the rerating. A better expression is to own qualified supply-chain bottlenecks while shorting the least-funded development exposure, but size the pair modestly because policy announcements or a financed customer order can create sharp upside squeezes in SMR.

Key Decisions for Investors

• Initiate a 6-12 month pair: long BWXT / short SMR, dollar-neutral. The thesis is earnings and backlog conversion versus financing and commercialization risk; target 15-25% relative outperformance, with a stop if SMR secures a fully financed binding commercial order or BWXT cuts margin/backlog-conversion guidance.
• Add BWXT only on 8-10% pullbacks or after evidence that acquired businesses are meeting synergy and margin targets; use a 12-18 month horizon. The key upside catalyst is upward EPS guidance from defense, fuel-processing, or acquisition contribution; risk is multiple compression if organic growth decelerates below low-double digits.
• For diversified nuclear exposure, favor a basket of BWXT, CCJ, LEU, and CW over reactor developers during the next 1-3 months. These companies capture spending on fuel, enrichment, components, and defense regardless of which SMR design ultimately wins; reassess if HALEU funding or Navy appropriations are delayed.
• Avoid outright SMR longs absent visibility on cash runway, contracted project economics, and customer financing. Monitor quarterly operating cash burn and new FEED/engineering awards; a material project award backed by non-recourse financing would invalidate the near-term bearish stance and warrant closing the short.